Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic CD19 CAR-T Cells for R/R B-ALL
NCT05164042Phase 2Unknown
- Sponsor
- Shenzhen University General Hospital
- Start
- Feb 2021
- Primary completion
- Feb 2024
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Shenzhen University General Hospital. Primary endpoint: Complete Remission Rate at 2 years. Status: unknown.
02
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT05164042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05164042.